Targeting neddylation as a novel approach to lung cancer treatment (Review)

Oudkerk M, Liu S, Heuvelmans MA, Walter JE and Field JK: Lung cancer LDCT screening and mortality reduction-evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 18:135–151. 2021. View Article : Google Scholar

Sachs E, Sartipy U and Jackson V: Sex and Survival After Surgery for Lung Cancer: A Swedish Nationwide Cohort. Chest. 159:2029–2039. 2021. View Article : Google Scholar :

Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI

Howington JA, Blum MG, Chang AC, Balekian AA and Murthy SC: Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143(5 Suppl): e278S–e313S. 2013. View Article : Google Scholar : PubMed/NCBI

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar

Watson IR, Irwin MS and Ohh M: NEDD8 pathways in cancer, Sine quibus non. Cancer Cell. 19:168–176. 2011. View Article : Google Scholar : PubMed/NCBI

Kamitani T, Kito K, Nguyen HP and Yeh ET: Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J Biol Chem. 272:28557–28562. 1997. View Article : Google Scholar : PubMed/NCBI

Chung D and Dellaire G: The Role of the COP9 Signalosome and Neddylation in DNA damage signaling and repair. Biomolecules. 5:2388–2416. 2015. View Article : Google Scholar : PubMed/NCBI

Zhou W, Xu J, Tan M, Li H, Li H, Wei W and Sun Y: UBE2M Is a Stress-Inducible Dual E2 for neddylation and ubiquitylation that promotes targeted degradation of UBE2F. Mol Cell. 70:1008–1024.e6. 2018. View Article : Google Scholar : PubMed/NCBI

Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, Borg LA, Neale G, Murray PJ, Roussel MF and Schulman BA: E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell. 33:483–495. 2009. View Article : Google Scholar : PubMed/NCBI

Xirodimas DP, Saville MK, Bourdon JC, Hay RT and Lane DP: Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 118:83–97. 2004. View Article : Google Scholar : PubMed/NCBI

Abida WM, Nikolaev A, Zhao W, Zhang W and Gu W: FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem. 282:1797–1804. 2007. View Article : Google Scholar

Lee GW, Park JB, Park SY, Seo J, Shin SH, Park JW, Kim SJ, Watanabe M and Chun YS: The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src. Oncogene. 37:5552–5568. 2018. View Article : Google Scholar : PubMed/NCBI

Broemer M, Tenev T, Rigbolt KT, Hempel S, Blagoev B, Silke J, Ditzel M and Meier P: Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases. Mol Cell. 40:810–822. 2010. View Article : Google Scholar : PubMed/NCBI

Keuss MJ, Thomas Y, Mcarthur R, Wood NT, Knebel A and Kurz T: Characterization of the mammalian family of DCN-type NEDD8 E3 ligases. J Cell Sci. 129:1441–1454. 2016.PubMed/NCBI

Meyer-Schaller N, Chou YC, Sumara I, Martin DD, Kurz T, Katheder N, Hofmann K, Berthiaume LG, Sicheri F and Peter M: The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes. Proc Natl Acad Sci USA. 106:12365–12370. 2009. View Article : Google Scholar : PubMed/NCBI

He S, Cao Y, Xie P, Dong G and Zhang L: The Nedd8 Non-covalent binding region in the smurf HECT domain is critical to its ubiquitn ligase function. Sci Rep. 7:413642017. View Article : Google Scholar : PubMed/NCBI

Deshaies RJ and Joazeiro CA: RING domain E3 ubiquitin ligases. Annu Rev Biochem. 78:399–434. 2009. View Article : Google Scholar : PubMed/NCBI

Soucy TA, Dick LR, Smith PG, Milhollen MA and Brownell JE: The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer. 1:708–716. 2010. View Article : Google Scholar

Mendoza HM, Shen LN, Botting C, Lewis A, Chen J, Ink B and Hay RT: NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J Biol Chem. 278:25637–25643. 2003. View Article : Google Scholar : PubMed/NCBI

Zhou L, Zhu J, Chen W, Jiang Y, Hu T, Wang Y, Ye X, Zhan M, Ji C, Xu Z, et al: Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity. Cell Death Dis. 11:9752020. View Article : Google Scholar : PubMed/NCBI

Zhou L, Jiang Y, Luo Q, Li L and Jia L: Neddylation: A novel modulator of the tumor microenvironment. Mol Cancer. 18:772019. View Article : Google Scholar : PubMed/NCBI

Duda DM, Scott DC, Calabrese MF, Zimmerman ES, Zheng N and Schulman BA: Structural regulation of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol. 21:257–264. 2011. View Article : Google Scholar : PubMed/NCBI

Furukawa M, Zhang Y, McCarville J, Ohta T and Xiong Y: The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1. Mol Cell Biol. 20:8185–8197. 2000. View Article : Google Scholar : PubMed/NCBI

Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M and Schulman BA: Structural insights into NEDD8 activation of cullin-RING ligases: Conformational control of conjugation. Cell. 134:995–1006. 2008. View Article : Google Scholar : PubMed/NCBI

Kim AY, Bommelje CC, Lee BE, Yonekawa Y, Choi L, Morris LG, Huang G, Kaufman A, Ryan RJ, Hao B, et al: SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. J Biol Chem. 283:33211–33220. 2008. View Article : Google Scholar : PubMed/NCBI

Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu J, Xiong Y and Zheng N: Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell. 119:517–528. 2004. View Article : Google Scholar : PubMed/NCBI

Feng S, Shen Y, Sullivan JA, Rubio V, Xiong Y, Sun TP and Deng XW: Arabidopsis CAND1, an unmodified CUL1-interacting protein, is involved in multiple developmental pathways controlled by ubiquitin/proteasome-mediated protein Degradation. Plant Cell. 16:1870–1882. 2004. View Article : Google Scholar : PubMed/NCBI

Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S and Eymin B: Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: Relationships with CAND1 and cyclin E protein levels. J Pathol. 213:303–310. 2007. View Article : Google Scholar : PubMed/NCBI

Li L, Kang J, Zhang W, Cai L, Wang S, Liang Y, Jiang Y, Liu X, Zhang Y, Ruan H, et al: Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. EBioMedicine. 45:81–91. 2019. View Article : Google Scholar : PubMed/NCBI

Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES and Chau V: A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA. 97:4579–4584. 2000. View Article : Google Scholar : PubMed/NCBI

Iso T, Suzuki T, Baird L and Yamamoto M: Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells. Mol Cell Biol. 36:3100–3112. 2016. View Article : Google Scholar : PubMed/NCBI

Bennett EJ, Rush J, Gygi SP and Harper JW: Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell. 143:951–965. 2010. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Morgan MA and Sun Y: Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal. 21:2383–2400. 2014. View Article : Google Scholar : PubMed/NCBI

Kang M, Li Y, Zhao Y, He S and Shi J: MiR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer. Clin Transl Oncol. 20:457–466. 2018. View Article : Google Scholar

Li L, Wang M, Yu G, Chen P, Li H, Wei D, Zhu J, Xie L, Jia H, Shi J, et al: Overactivated neddylation pathway as a therapeutic target in lung cancer. J Natl Cancer Inst. 106:dju0832014. View Article : Google Scholar : PubMed/NCBI

Watson IR, Li BK, Roche O, Blanch A, Ohh M and Irwin MS: Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene. 29:297–304. 2010. View Article : Google Scholar

Xie P, Zhang M, He S, Lu K, Chen Y, Xing G, Lu Y, Liu P, Li Y, Wang S, et al: The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis. Nat Commun. 5:37332014. View Article : Google Scholar : PubMed/NCBI

Mahata B, Sundqvist A and Xirodimas DP: Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner. Oncogene. 31:3060–3071. 2012. View Article : Google Scholar

Sundqvist A, Liu G, Mirsaliotis A and Xirodimas DP: Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep. 10:1132–1139. 2009. View Article : Google Scholar : PubMed/NCBI

Zhang J, Bai D, Ma X, Guan J and Zheng X: hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Oncogene. 33:246–254. 2014. View Article : Google Scholar

Deben C, Deschoolmeester V, Lardon F, Rolfo C and Pauwels P: TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Crit Rev Oncol Hematol. 99:63–73. 2016. View Article : Google Scholar

Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[Kappa]B activity. Annu Rev Immunol. 18:621–663. 2000. View Article : Google Scholar

Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V and Palombella VJ: Nedd8 Modification of Cul-1 Activates SCF(beta(TrCP)-Dependent Ubiquitination of IkappaBalpha. Mol Cell Biol. 20:2326–2333. 2000. View Article : Google Scholar : PubMed/NCBI

Yu H, Lin L, Zhang Z, Zhang H and Hu H: Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther. 5:2092020. View Article : Google Scholar

Zhou L, Jiang Y, Liu X, Li L, Yang X, Dong C, Liu X, Lin Y, Li Y, Yu J, et al: Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer. Oncogene. 38:5792–5804. 2019. View Article : Google Scholar : PubMed/NCBI

Liu W, Wang H, Bai F, Ding L, Huang Y, Lu C, Chen S, Li C, Yue X, Liang X, et al: IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB. Cell Prolif. 53:e127762020. View Article : Google Scholar

Orel L, Neumeier H, Hochrainer K, Binder BR and Schmid JA: Crosstalk between the NF-kappaB activating IKK-complex and the CSN signalosome. J Cell Mol Med. 14:1555–1568. 2010. View Article : Google Scholar

Ediriweera MK, Tennekoon KH and Samarakoon SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI

Chibaya L, Karim B, Zhang H and Jones SN: Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis. Proc Natl Acad Sci USA. 118:e20031931182021. View Article : Google Scholar : PubMed/NCBI

Xie P, Peng Z, Chen Y, Li H, Du M, Tan Y, Zhang X, Lu Z, Cui CP, Liu CH, et al: Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell Res. 31:291–311. 2021. View Article : Google Scholar :

Li X, Li C, Guo C, Zhao Q, Cao J, Huang HY, Yue M, Xue Y, Jin Y, Hu L and Ji H: PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer. J Genet Genomics. 48:640–651. 2021. View Article : Google Scholar : PubMed/NCBI

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic molecular profile of tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Bian Y, Wang Y, Wang Y, Duan X, Han Y, Zhang L, Wang F, Gu Z and Qin Z: HIF-1α is necessary for activation and tumour-promotion effect of cancer-associated fibroblasts in lung cancer. J Cell Mol Med. 25:5457–5469. 2021. View Article : Google Scholar : PubMed/NCBI

Wan J and Wu W: Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways. J Exp Clin Cancer Res. 35:1192016. View Article : Google Scholar : PubMed/NCBI

Curtis VF, Ehrentraut SF, Campbell EL, Glover LE, Bayless A, Kelly CJ, Kominsky DJ and Colgan SP: Stabilization of HIF through inhibition of Cullin-2 neddylation is protective in mucosal inflammatory responses. FASEB J. 29:208–215. 2015. View Article : Google Scholar :

Russell RC and Ohh M: NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL. EMBO Rep. 9:486–491. 2008. View Article : Google Scholar : PubMed/NCBI

Wolf ER, Mabry AR, Damania B and Mayo LD: Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors. Oncogene. 39:5228–5239. 2020. View Article : Google Scholar : PubMed/NCBI

Hsu PC, Yang CT, Jablons DM and You L: The Crosstalk between Src and Hippo/YAP signaling pathways in non-small cell lung cancer (NSCLC). Cancers (Basel). 12:13612020. View Article : Google Scholar : PubMed/NCBI

Zou J, Ma W, Li J, Littlejohn R, Zhou H, Kim IM, Fulton DJR, Chen W, Weintraub NL, Zhou J and Su H: Neddylation mediates ventricular chamber maturation through repression of Hippo signaling. Proc Natl Acad Sci USA. 115:E4101–E4110. 2018. View Article : Google Scholar : PubMed/NCBI

Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, et al: Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Mol Cancer Ther. 16:1693–1704. 2017. View Article : Google Scholar : PubMed/NCBI

Maehama T, Nishio M, Otani J, Mak TW and Suzuki A: The role of Hippo-YAP signaling in squamous cell carcinomas. Cancer Sci. 112:51–60. 2021. View Article : Google Scholar

Du Z and Lovly CM: Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 17:582018. View Article : Google Scholar : PubMed/NCBI

Shi Q and Chen YG: Interplay between TGF-β signaling and receptor tyrosine kinases in tumor development. Sci China Life Sci. 60:1133–1141. 2017. View Article : Google Scholar : PubMed/NCBI

Enchev RI, Schulman BA and Peter M: Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 16:30–44. 2015. View Article : Google Scholar

Hamon P, Thoré MGD, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Clémenson C, Milliat F, Deutsch E and Mondini M: TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer. 10:e0035192022. View Article : Google Scholar

Zuo W, Huang F, Chiang YJ, Li M, Du J, Ding Y, Zhang T, Lee HW, Jeong LS, Chen Y, et al: c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. Mol Cell. 49:499–510. 2013. View Article : Google Scholar : PubMed/NCBI

Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G and Yarden Y: Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem. 281:21640–21651. 2006. View Article : Google Scholar : PubMed/NCBI

Tumbrink HL, Heimsoeth A and Sos ML: The next tier of EGFR resistance mutations in lung cancer. Oncogene. 40:1–11. 2021. View Article : Google Scholar

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, et al: EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov. 6:601–611. 2016. View Article : Google Scholar : PubMed/NCBI

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI

Invrea F, Punzi S, Petti C, Minelli R, Peoples MD, Bristow CA, Vurchio V, Corrado A, Bragoni A, Marchiò C, et al: Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of NEDD8 and EGFR pathways. Cancers (Basel). 13:38052021. View Article : Google Scholar : PubMed/NCBI

Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, et al: Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol. 36:349–364. 2020. View Article : Google Scholar : PubMed/NCBI

Bommelje CC, Weeda VB, Huang G, Shah K, Bains S, Buss E, Shaha M, Gönen M, Ghossein R, Ramanathan SY and Singh B: Oncogenic function of SCCRO5/DCUN1D5 requires its Neddylation E3 activity and nuclear localization. Clin Cancer Res. 20:372–381. 2014. View Article : Google Scholar :

Wang L, Zhang M, Pan X, Zhao M, Huang L, Hu X, Wang X, Qiao L, Guo Q, Xu W, et al: Integrative serum metabolic fingerprints based multi-modal platforms for lung adenocarcinoma early detection and pulmonary nodule classification. Adv Sci (Weinh). 9:e22037862022. View Article : Google Scholar : PubMed/NCBI

Yang J, Yin X, Zhang L, Zhang X, Lin Y, Zhuang L, Liu W, Zhang R, Yan X, Shi L, et al: Defective Fe metal-organic frameworks enhance metabolic profiling for high-accuracy diagnosis of human cancers. Adv Mater. 34:e22014222022. View Article : Google Scholar : PubMed/NCBI

Zhou L, Dong C, Xu Z, Wang X, Zhang L, Chen S, Chen J and Zhu Y: NEDD8-conjugating enzyme E2 UBE2F confers radiation resistance by protecting lung cancer cells from apoptosis. J Zhejiang Univ Sci B. 22:959–965. 2021. View Article : Google Scholar : PubMed/NCBI

Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, Pan Z and Sun Y: Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to Degrade NOXA via the K11 Linkage. Clin Cancer Res. 23:1104–1116. 2017. View Article : Google Scholar :

Guo ZP, Hu YC, Xie Y, Jin F, Song ZQ, Liu XD, Ma T and Zhou PK: MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells. Biochem Biophys Res Commun. 483:223–229. 2017. View Article : Google Scholar

Meng F, Yu W, Chen C, Guo S, Tian X, Miao Y, Ma L, Zhang X, Yu Y, Huang L, et al: A versatile electrochemical biosensor for the detection of circulating MicroRNA toward non-small cell lung cancer diagnosis. Small. 18:e22007842022. View Article : Google Scholar : PubMed/NCBI

Zhu HZ, Hou J, Guo Y, Liu X, Jiang FL, Chen GP, Pang XF, Sun JG and Chen ZT: Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles. Drug Deliv. 25:1974–1983. 2018. View Article : Google Scholar

Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, et al: Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 29:1981–1992. 2015. View Article : Google Scholar : PubMed/NCBI

Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, et al: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst. 99:847–857. 2007. View Article : Google Scholar : PubMed/NCBI

Xu W, Xie X, Wu H, et al: Pulsed electromagnetic therapy in cancer treatment: Progress and outlook. View. 3:202200292022. View Article : Google Scholar

Brownell J E, Sintcha k MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, et al: Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 37:102–111. 2010. View Article : Google Scholar : PubMed/NCBI

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, et al: Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 37:87–97. 2019. View Article : Google Scholar :

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, et al: Phase I study of the investigational NEDD8-Activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin Cancer Res. 22:847–857. 2016. View Article : Google Scholar

Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X and Sun Y: The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci USA. 116:20528–20538. 2019. View Article : Google Scholar : PubMed/NCBI

Norton JP, Augert A, Eastwood E, Basom Rudin CM and MacPherson D: Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas. Genes Dev. 35:870–887. 2021. View Article : Google Scholar : PubMed/NCBI

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI

Jia L, Li H and Sun Y: Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 13:561–569. 2011. View Article : Google Scholar : PubMed/NCBI

Lin JJ, Milhollen MA, Smith PG, Narayanan U and Dutta A: NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70:10310–10320. 2010. View Article : Google Scholar : PubMed/NCBI

Chen P, Hu T, Liang Y, Li P, Chen X, Zhang J, Ma Y, Hao Q, Wang J, Zhang P, et al: Neddylation inhibition activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5 axis in human esophageal cancer cells. Clin Cancer Res. 22:4145–4157. 2016. View Article : Google Scholar : PubMed/NCBI

Jia L, Soengas MS and Sun Y: ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 69:4974–4982. 2009. View Article : Google Scholar : PubMed/NCBI

Rizzardi LF and Cook JG: Flipping the switch from g1 to s phase with e3 ubiquitin ligases. Genes Cancer. 3:634–648. 2012. View Article : Google Scholar

Zhao Y, Xiong X, Jia L and Sun Y: Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 3:e3862012. View Article : Google Scholar : PubMed/NCBI

Li Y, Wang C, Xu T, Pan P, Yu Q, Xu L, Xiong X, Hou T, Cui S and Sun Y: Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy. Acta Pharm Sin B. 11:3567–3584. 2021. View Article : Google Scholar : PubMed/NCBI

Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI

Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, et al: Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis. 5:e10592014. View Article : Google Scholar : PubMed/NCBI

Tan M, Zhao Y, Kim SJ, Liu M, Jia L, Saunders TL, Zhu Y and Sun Y: SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell. 21:1062–1076. 2011. View Article : Google Scholar : PubMed/NCBI

Tan M, Li H and Sun Y: Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis. Oncogene. 33:5211–5220. 2014. View Article : Google Scholar :

Conway EM, Pikor LA, Kung SH, Hamilton MJ, Lam S, Lam WL and Bennewith KL: Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 193:116–130. 2016. View Article : Google Scholar

Deng Q, Zhang J, Gao Y, She X, Wang Y, Wang Y and Ge X: MLN4924 protects against bleomycin-induced pulmonary fibrosis by inhibiting the early inflammatory process. Am J Transl Res. 9:1810–1821. 2017.PubMed/NCBI

Zhou L, Zhang W, Sun Y and Jia L: Protein neddylation and its alterations in human cancers for targeted therapy. Cell Signal. 44:92–102. 2018. View Article : Google Scholar : PubMed/NCBI

Hao R, Song Y, Li R, Wu Y, Yang X, Li X, Qian F, Ye RD and Sun L: MLN4924 protects against interleukin-17A-induced pulmonary inflammation by disrupting ACT1-mediated signaling. Am J Physiol Lung Cell Mol Physiol. 316:L1070–L1080. 2019. View Article : Google Scholar : PubMed/NCBI

Cheng M, Hu S, Wang Z, Pei Y, Fan R, Liu X, Wang L, Zhou J, Zheng S, Zhang T, et al: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation. Oncotarget. 7:35643–35654. 2016. View Article : Google Scholar : PubMed/NCBI

Mathewson N, Toubai T, Kapeles S, Sun Y, Oravecz-Wilson K, Tamaki H, Wang Y, Hou G, Sun Y and Reddy P: Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood. 122:2062–2073. 2013. View Article : Google Scholar : PubMed/NCBI

Zhu Z, Sun L, Hao R, Jiang H, Qian F and Ye RD: Nedd8 modification of Cullin-5 regulates lipopolysaccharide-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 313:L104–L114. 2017. View Article : Google Scholar : PubMed/NCBI

Jiang Y, Liang Y, Li L, Zhou L, Cheng W, Yang X, Yang X, Qi H, Yu J, Jeong LS, et al: Targeting neddylation inhibits intra-vascular survival and extravasation of cancer cells to prevent lung-cancer metastasis. Cell Biol Toxicol. 35:233–245. 2019. View Article : Google Scholar : PubMed/NCBI

Kim Y, Park JB, Fukuda J, Watanabe M and Chun YS: The effect of neddylation blockade on slug-dependent cancer cell migration is regulated by p53 mutation status. Cancers (Basel). 13:5312021. View Article : Google Scholar : PubMed/NCBI

Sun Y and Li H: Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell. 4:103–116. 2013. View Article : Google Scholar

Xu Q, Lin G, Xu H, Hu L, Wang Y, Du S, Deng W, Hu W, Cheng W and Jiang K: MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells. Oncol Lett. 15:515–521. 2018.PubMed/NCBI

Zhang Q, Karnak D, Tan M, Lawrence TS, Morgan MA and Sun Y: FBXW7 facilitates nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell. 61:419–433. 2016. View Article : Google Scholar : PubMed/NCBI

Zhou X, Tan M, Nyati MK, Zhao Y, Wang G and Sun Y: Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo. Proc Natl Acad Sci USA. 113:E2935–2944. 2016. View Article : Google Scholar : PubMed/NCBI

Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI

Park JB, Seo J, Park JW and Chun YS: Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1. Sci Rep. 10:182102020. View Article : Google Scholar

Korrodi-Gregório L, Soto-Cerrato V, Vitorino R, Fardilha M and Pérez-Tomás R: From proteomic analysis to potential therapeutic targets: Functional profile of two lung cancer cell lines, A549 and SW900, widely studied in pre-clinical research. PLoS One. 11:e01659732016. View Article : Google Scholar : PubMed/NCBI

Ni S, Chen X, Yu Q, Xu Y, Hu Z, Zhang J, Zhang W, Li B, Yang X, Mao F, et al: Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth. Eur J Med Chem. 185:1118482020. View Article : Google Scholar

Chen X, Yang X, Mao F, Wei J, Xu Y, Li B, Zhu J, Ni S, Jia L and Li J: Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo. Eur J Med Chem. 210:1129642021. View Article : Google Scholar

An H and Statsyuk AV: An inhibitor of ubiquitin conjugation and aggresome formation. Chem Sci. 6:5235–5245. 2015. View Article : Google Scholar : PubMed/NCBI

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, et al: Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell. 21:388–401. 2012. View Article : Google Scholar : PubMed/NCBI

Toth JI, Yang L, Dahl R and Petroski MD: A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep. 1:309–316. 2012. View Article : Google Scholar : PubMed/NCBI

Verma S, Singh A and Mishra A: Molecular dynamics investigation on the poor sensitivity of A171T mutant NEDD8-activating enzyme (NAE) for MLN4924. J Biomol Struct Dyn. 32:1064–1073. 2014. View Article : Google Scholar

Hammill JT, Scott DC, Min J, Connelly MC, Holbrook G, Zhu F, Matheny A, Yang L, Singh B, Schulman BA and Guy RK: Piperidinyl ureas chemically control defective in cullin neddylation 1 (DCN1)-Mediated cullin neddylation. J Med Chem. 61:2680–2693. 2018. View Article : Google Scholar : PubMed/NCBI

Hammill JT, Bhasin D, Scott DC, Min J, Chen Y, Lu Y, Yang L, Kim HS, Connelly MC, Hammill C, et al: Discovery of an orally bioavailable inhibitor of defective in cullin neddylation 1 (DCN1)-Mediated cullin neddylation. J Med Chem. 61:2694–2706. 2018. View Article : Google Scholar : PubMed/NCBI

Zhou H, Lu J, Liu L, Bernard D, Yang CY, Fernandez-Salas E, Chinnaswamy K, Layton S, Stuckey J, Yu Q, et al: A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. Nat Commun. 8:11502017. View Article : Google Scholar : PubMed/NCBI

Zhou H, Lu J, Chinnaswamy K, Stuckey JA, Liu L, McEachern D, Yang CY, Bernard D, Shen H, Rui L, et al: Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. Nat Commun. 12:26212021. View Article : Google Scholar : PubMed/NCBI

Li Y, Bao Q, Yang S, Yang M and Mao C: Bionanoparticles in cancer imaging, diagnosis, and treatment. View. 3:202000272022. View Article : Google Scholar

Zhang Z, Zhang J, Tian J and Li H: A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1). J Nanobiotechnology. 19:3232021. View Article : Google Scholar : PubMed/NCBI

Deng L, Meng T, Chen L, Wei W and Wang P: The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 5:112020. View Article : Google Scholar : PubMed/NCBI